H.R. 7658
Referred to CommitteeTo amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
Introduced 5/3/2022•117th Congress•House
Latest Action
Referred to the House Committee on Energy and Commerce.
5/3/2022 • House
Summary
This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.
Introduced in House • 5/3/2022
Enter your district to see how this bill affects your community
Topics & Subjects
Policy Area: Health
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (2)
Party Breakdown
1
Democrats
1
Republicans
0
Independents
Sponsor
R[
Cosponsors (1)
R[
Bill Journey
Originated in the House
Introduced
May 3, 2022
Referred to the House Committee on Energy and Commerce.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Introduced in House5/3/2022